Conference Coverage
The Latest
How a Midwestern HIV Clinic Rapidly Adjusted to the Spreading COVID-19 Pandemic
At the University of Nebraska Medical Center, HIV care providers scrambled to set up new systems in hopes of maintaining retention in care and viral suppression among as many patients as possible.
How Can We Manage Pain Better in Older Adults Living With HIV?
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
HIV Incidence Is Lower in States With More Generous Low-Income Food Benefits
“The message that needs to be communicated to people in power, and it needs to be communicated loud and frequently, is, ‘Look. Here’s the actual human cost of not enacting these kinds of policies. Here’s the potential benefit,’” says Aaron Richterman, M.D., M.P.H.
Histoplasmosis and HIV in the U.S.: Often Forgotten, Never Gone
IDWeek 2020 provided a perfect opportunity to better understand the modern-day impact of histoplasmosis among Americans living with HIV—and to bone up on the basics.
For PrEP to Work, Shared Doctor-Patient Decision-Making Is Key
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
U.S. Homeless Shelters Are Key Centers for HIV and Tuberculosis Prevention, Experts Say
HIV and TB often go hand in hand among people experiencing homelessness in the U.S.—a reality that gives public health officials an opportunity to utilize shelters in tackling both viruses at the same time.
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
Flurry of New Research Explores Weight Gain on Integrase Inhibitors Among People Living With HIV
Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.
More Research Points to Weight Increases on TAF-Containing HIV Treatment
Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.
HIV Status Does Not Affect COVID-19 Hospitalization, Short-Term Outcomes in Connecticut Hospital
The findings add to a growing body of research showing that it’s other co-morbidities, not HIV, that lead to worse health outcomes from COVID-19—at least among individuals who are on stable antiretroviral therapy.